Parkinson's Disease Global Market Report 2025

The parkinson's disease market size has grown strongly in recent years. It will grow from $3.34 billion in 2024 to $3.63 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the increase in research and development, a rise in government funding, the expansion of personalized treatment plans, the growth of support networks for Parkinson's disease patients, and the increased use of advanced rehabilitation therapies.

The parkinson's disease market size is expected to see strong growth in the next few years. It will grow to $4.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth projected for the forecast period is driven by increased awareness of Parkinson’s disease symptoms, enhanced government initiatives, rising healthcare spending, a growing number of clinical trials for Parkinson’s disease, and greater adoption of gene therapies. Key trends during this period include technological advancements, continued government initiatives and funding, the integration of artificial intelligence in diagnosis, innovative solutions, and a move toward personalized medicine.

The increasing prevalence of neurodegenerative diseases is expected to drive the growth of the Parkinson’s disease market. Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration and loss of function of neurons in the brain and nervous system. Several factors contribute to the rising prevalence of these conditions, including an aging population, genetic predisposition, environmental influences, improved diagnosis, chronic health conditions, and lifestyle changes. Parkinson’s disease plays a crucial role in advancing the understanding of neurodegenerative diseases by offering insights into their underlying mechanisms, identifying potential therapeutic targets, and developing innovative treatment approaches. For instance, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions affect millions globally, with 65 million people suffering from epilepsy. In Europe alone, 10.5 million people have dementia, with projections indicating an increase to 18.7 million by 2050. As a result, the rising prevalence of neurodegenerative diseases is fueling the expansion of the Parkinson’s disease market.

Leading companies in the Parkinson’s disease market are focusing on innovative treatment solutions, such as levodopa-based therapy, to enhance motor function and provide continuous symptom management for patients with advanced Parkinson’s disease. Levodopa-based therapy involves using levodopa, a medication that converts into dopamine in the brain, to alleviate symptoms and improve motor function. For example, in October 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, received FDA approval for VYALEV, a combination therapy containing levodopa and carbidopa designed for treating Parkinson’s disease. This formulation enhances the efficacy of levodopa by preventing its breakdown before reaching the brain, thereby increasing dopamine levels. The medication effectively manages motor symptoms such as tremors, rigidity, and bradykinesia, helping patients maintain daily activities and improving their quality of life. It is considered a key therapeutic solution for patients with Parkinson’s disease experiencing motor fluctuations.

In August 2024, AbbVie Inc. expanded its neuroscience portfolio by acquiring Cerevel Therapeutics Holdings Inc., a US-based biotechnology company specializing in treatments for Parkinson’s disease. This acquisition aims to strengthen AbbVie’s position in addressing unmet medical needs in psychiatric and neurological disorders, reinforcing its commitment to developing innovative therapies for neurodegenerative diseases.

Major players in the parkinson's disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

North America was the largest region in the parkinson's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in parkinson's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the parkinson's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Parkinson's disease is a degenerative neurological disorder that impacts movement due to the loss of dopamine-producing cells in the brain. It primarily results in tremors, muscle stiffness, slowed movements, and balance issues. Treatment typically includes medications such as levodopa to manage symptoms, often supplemented with physical therapy and, in some cases, surgical options such as deep brain stimulation.

The main classes of drugs used to treat Parkinson's disease consist of dopamine agonists, catechol-O-methyltransferase inhibitors, monoamine oxidase B inhibitors, anticholinergics, carbidopa-levodopa, and others. Dopamine agonists, for example, mimic dopamine's effects in the brain to help control symptoms. These drugs can be administered via various routes, including oral, injectable, intestinal infusion, subcutaneous, and other methods, depending on treatment requirements. Additionally, the distribution channels for Parkinson's disease medications include retail pharmacies, hospital pharmacies, and online pharmacies, ensuring broad accessibility. Most patient care for Parkinson's disease is managed in clinics and hospitals, where healthcare professionals can closely monitor and treat the condition.

The parkinson’s disease market research report is one of a series of new reports that provides parkinson’s disease market statistics, including parkinson’s disease industry global market size, regional shares, competitors with a parkinson’s disease market share, detailed parkinson’s disease market segments, market trends and opportunities, and any further data you may need to thrive in the parkinson’s disease industry. This parkinson’s disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The parkinson's disease market consists of revenues earned by entities providing services such as speech therapy, and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The parkinson's disease market also includes sales of amantadine and adenosine A2A receptor antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.